scholarly journals Rapid Progression of a Urinary Bladder Leiomyosarcoma: Report of a Case

2011 ◽  
Vol 2011 ◽  
pp. 1-3
Author(s):  
Toru Yamada ◽  
Shingo Nagai ◽  
Yusuke Kanimoto
Keyword(s):  
Bladder Tumor ◽  
Clinical Status ◽  
Rapid Progression ◽  
Histopathological Diagnosis ◽  
Macroscopic Hematuria ◽  
Exertional Dyspnea ◽  
Metastatic Lesions ◽  
Pelvic Wall ◽  
Visceral Metastases ◽  
Wall Invasion

The case we report shows rapid progression and a very poor prognosis only for a month that differs from the clinical course reported in the literature. An 83-year-old man was referred to our hospital for macroscopic hematuria. Computed tomography (CT) revealed a large bladder tumor measuring 4 cm × 3 cm and magnetic resonance imaging revealed extravesical invasion and pelvic wall invasion of the tumors. Chest CT and bone scintigraphy revealed no evidence of distant visceral metastases, and a clinical diagnosis of T4N0M0 was made. Transurethral resection of the bladder tumor (TUR-BT) was performed for histopathological diagnosis 18 days after admission, and no further adjuvant treatment was given. At 15 days after TUR-BT, the patient's clinical status worsened with symptoms of exertional dyspnea. CT showed multiple metastatic lesions in the lung, liver, and retroperitoneal lymphadenopathy. The patient died 2 days later and underwent autopsy. A final histopathological diagnosis of leiomyosarcoma was made based on immunohistochemical staining.

scholarly journals Inflammatory Myofibroblastic Bladder Tumor in a Patient with Von Recklinghausen's Syndrome

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Eleftherios Chatzidarellis ◽  
Evangelos Mazaris ◽  
Andreas Skolarikos ◽  
Demonakou Maria ◽  
Iraklis Mitsogiannis ◽  
...  
Keyword(s):  
Transurethral Resection ◽  
Inflammatory Myofibroblastic Tumor ◽  
Bladder Tumor ◽  
Inflammatory Pseudotumor ◽  
Benign Tumor ◽  
Pathologic Examination ◽  
Bladder Tumors ◽  
Macroscopic Hematuria ◽  
History Of ◽  
Suprapubic Prostatectomy

Myofibroblastic tumor, also known as inflammatory pseudotumor or pseudosarcoma, is a benign tumor with mesenchymal origin. Bladder location is very uncommon. We report the case of a 58-year-old man with a history of von Recklinghausen's disease who complained for painless macroscopic hematuria 5 months after suprapubic prostatectomy. The radiograph evaluation revealed a bladder tumor, and the pathologic examination following a transurethral resection showed inflammatory myofibroblastic tumor of the bladder. The patient finally underwent a radical cystectomy due to the uncertain pathogenesis of inflammatory myofibroblastic tumor as well as the rarity of cases published on bladder tumors in Von Recklinghausen's patients.

A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report

Lupus ◽  
2016 ◽  
Vol 26 (7) ◽  
pp. 777-782 ◽  
Author(s):  
X-J Zhou ◽  
M Chen ◽  
S-X Wang ◽  
F-D Zhou ◽  
M-H Zhao
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Case Report ◽  
Plasma Exchange ◽  
Thrombotic Microangiopathy ◽  
Rapid Progression ◽  
Histopathological Diagnosis ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome

Background Microvascular manifestations of antiphospholipid antibody syndrome in the kidneys include acute renal failure, thrombotic microangiopathy and hypertension. Therapy has been largely empiric. Case report A 49-year-old Chinese man presented with anuric acute renal failure without abundant proteinuria and heavy haematuria, but markedly low levels of urinary sodium, potassium and chlorine upon admission. On day 1 of hospitalization, his thrombocytopenia, anaemia and renal failure showed rapid progression. The presence of lupus anticoagulant and vascular ischaemia of the small vessels in renal arteriography were also observed. Anticoagulants, continuous renal replacement therapy, glucocorticoids and six sessions of plasma exchange were started. After the fourth plasma exchange (on day 20), his urine output increased and began to normalize. On day 25, haemodialysis was stopped and his general condition gradually improved. A renal biopsy was subsequently performed, and the histopathological diagnosis was thrombotic microangiopathy due to antiphospholipid antibody syndrome. A further 3-year follow-up showed that his haemoglobin level, platelet count and serum creatinine were within the normal range, with stable blood pressure. Conclusion Treatment modalities such as anticoagulation, immunosuppression and plasma exchange are likely to be necessary when severe acute renal failure combined with thrombotic microangiopathy present in nephropathy of antiphospholipid antibody syndrome.

CEA as a pharmacodynamic biomarker for metastatic anal cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 684-684 ◽  
Author(s):  
Robert Harrison Hester ◽  
Cullen M. Taniguchi ◽  
Emma Brey Holliday ◽  
Eugene Jon Koay ◽  
Prajnan Das ◽  
...  
Keyword(s):  
Colorectal Adenocarcinoma ◽  
Clinical Status ◽  
Locally Advanced ◽  
Immune Checkpoint Blockade ◽  
Tumor Burden ◽  
Newly Diagnosed ◽  
Chi Squared ◽  
Visceral Metastases ◽  
Associated Malignancy ◽  
Proven Benefit

684 Background: While carcinoembryonic antigen (CEA) as a tumor marker is frequently used in the management of colorectal adenocarcinoma, its clinical utility in squamous cell carcinoma of the anus (SCCA) has never been reported. Indeed, no tumor markers have been validated for monitoring tumor burden in the course of any HPV-associated malignancy like SCCA. We hypothesized that CEA levels might be preferentially elevated in patients with metastatic SCCA. Methods: Charts from 212 patients with SCCA were reviewed under an IRB-approved protocol for correlations between CEA levels and corresponding oncologic status. Clinical status was categorized as newly diagnosed non-metastatic (D), after chemoradiation with no evident remnant disease (N), recurrent/resectable SCCA (R), locally advanced/unresectable SCCA (U), metastatic SCCA to lymph nodes only (M-LN), or metastatic SCCA to visceral organs (M-V). Mean CEA levels were compared between subgroups via student t-tests, and frequencies of elevated CEA were compared via Chi-squared analyses. Results: 118 SCCA patients had metastatic disease (98 M-V, 19 M-LN). Mean CEA levels by clinical status were 5.4 (D), 2.0 (N), 2.3 (R), 4.6 (U), 6.0 (M-LN), and 22.2 (M-V), with a higher (statistically insignificant) mean CEA level in the M-V relative to other populations. However, patients with visceral metastases were more likely to have an elevated CEA at presentation (40.4%) relative to patients with newly diagnosed, non-metastatic SCCA (17.6%, p = .07) or recurrent SCCA (11.1%, p = .02). For patients with metastatic SCCA, a significant association existed between change in CEA and corresponding change in radiographic tumor dimensions (OR 24, p < 0.0001). Conclusions: Trends in CEA correlate with dynamic changes in tumor burden for patients with metastatic SCCA, and patients with metastatic SCCA were more likely to have an elevated CEA. Given that immune checkpoint blockade agents like nivolumab have proven benefit for metastatic SCCA, these data provide rationale for use of newer generation immunotherapeutic approaches like CEA-T cell bispecific antibodies, which target CEA-expressing tumors, in clinical trials for patients with metastatic SCCA.

scholarly journals Lymphoepithelioma-Like Carcinoma of the Bladder: A Case Report and Review of the Literature

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Kenichi Mori ◽  
Tadasuke Ando ◽  
Takeo Nomura ◽  
Fuminori Sato ◽  
Hiromitsu Mimata
Keyword(s):  
Urothelial Carcinoma ◽  
Bladder Tumor ◽  
Ileal Conduit ◽  
Tumor Resection ◽  
High Grade ◽  
Review Of The Literature ◽  
Macroscopic Hematuria ◽  
Pathological Evaluation ◽  
Carcinoma Of The Bladder ◽  
Bladder Carcinomas

Lymphoepithelioma-like carcinoma (LELC) in the bladder is uncommon with a reported incidence of 0.4%–1.3% of all bladder carcinomas. In Japan, some occurrences of LELC have been reported in the renal pelvis and ureter but only two in the bladder. A bladder tumor was identified in a 70-year-old man suffering from macroscopic hematuria for 2 months. Sections of the transurethral tumor resection showed invasive high-grade urothelial carcinoma. The patient was diagnosed with local invasive bladder tumor, and cystectomy with ileal conduit formation was performed. The final pathological evaluation was predominant LELC with urothelial carcinoma. We present a new case of LELC in the bladder and performed a review of all published cases of LELC in the urinary tract to obtain its characteristics and prognostic guide.

scholarly journals Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature

2021 ◽  
pp. FSO707
Author(s):  
Emilie Delchambre ◽  
Stéphane Rysselinck ◽  
Géraldine Pairet ◽  
Caterina Confente ◽  
Emmanuel Seront
Keyword(s):  
Prostate Cancer ◽  
Peritoneal Carcinomatosis ◽  
Complete Response ◽  
Abiraterone Acetate ◽  
Review Of The Literature ◽  
Metastatic Lesions ◽  
Psma Pet ◽  
Visceral Metastases ◽  
History Of ◽  
Late Stages

Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal carcinomatosis is rarely described in literature, particularly when not associated with other distant metastatic lesions. We present the management of a patient with prostate cancer progressing on androgen deprivation therapy with description of omental involvement on 68Ga PSMA-PET. There was no ascite or other distant lesion, reflecting thus a specific tropism of the cancer in this patient who had no history of prostate surgery. Abiraterone acetate resulted in a long-lasting complete response. We also present a review focusing on this entity.

scholarly journals Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 779 ◽  
Author(s):  
Asta Juzeniene ◽  
Vilde Yuli Stenberg ◽  
Øyvind Sverre Bruland ◽  
Roy Hartvig Larsen
Keyword(s):  
Prostate Cancer ◽  
Clinical Status ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Visceral Metastases ◽  
Castrate Resistant Prostate Cancer ◽  
Castrate Resistant ◽  
Specific Membrane ◽  
Clinical Advances ◽  
Made In

Bone, lymph node, and visceral metastases are frequent in castrate-resistant prostate cancer patients. Since such patients have only a few months’ survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β− therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT.

scholarly journals Multiple Metastases Gestational Choriocarcinoma - A Case Report

2018 ◽  
Vol 1 (Supplement) ◽  
pp. 1
Author(s):  
C. Mehedințu ◽  
M.M. Cîrstoiu ◽  
E. Brătilă ◽  
M. Plotogea ◽  
M. Antonovici ◽  
...  
Keyword(s):  
Hydatidiform Mole ◽  
Rapid Progression ◽  
X Rays ◽  
Trophoblastic Cells ◽  
Gestational Choriocarcinoma ◽  
Metastatic Lesions ◽  
Multiple Metastases ◽  
Detection And Diagnosis ◽  
Early Detection And Diagnosis

Abstract Introduction. Gestational choriocarcinoma (GC) is a malignant condition that develops form trophoblastic cells originating from a previous pregnancy, eutopic or ectopic. Metastatic choriocarcinoma is often diagnosed in the absence of a primary uterine or ovarian tumor, presumably because the latter has undergone complete necrosis. GC rapidly metastasizes spreading to lungs, brain, bones, bone marrow, liver, and other organs, but responds well to chemotherapy. Material and methods. We present the case of a 25-year-old woman with critical evolution after being diagnosed with choriocarcinoma following a complete hydatidiform mole pregnancy. Even though the patient initially received proper treatment, due to poor follow-up compliance, the condition led to invasive metastases. When it spread to the musculoskeletal system and other organs, doctors were able to link symptoms to the choriocarcinoma diagnosis and chemotherapy was initiated. Unfortunately, the patient succumbed due to intracranial hemorrhage. Discussions. GC is a highly and fast invasive malignancy, with rapidly growing tumors. It is often associated with hemorrhage, ischemic necrosis, and secondary inflammation. Often, by the time the tumor is discovered, X-rays of the chest and bones already show metastatic lesions. Chemotherapy success depends on early detection and diagnosis of tumors after pregnancy. Conclusions. Even though the initial diagnosis and treatment should have led to a favorable outcome, the patient’s poor compliance was followed by rapid progression of the disease and, finally, exitus.

scholarly journals Multiple Metastases Gestational Choriocarcinoma - A Case Report

2018 ◽  
Vol 1 (Supplement) ◽  
pp. 30
Author(s):  
C. Mehedințu ◽  
M.M. Cîrstoiu ◽  
E. Brătilă ◽  
M. Plotogea ◽  
M. Antonovici ◽  
...  
Keyword(s):  
Hydatidiform Mole ◽  
Rapid Progression ◽  
X Rays ◽  
Trophoblastic Cells ◽  
Gestational Choriocarcinoma ◽  
Metastatic Lesions ◽  
Multiple Metastases ◽  
Detection And Diagnosis ◽  
Early Detection And Diagnosis

Abstract Introduction. Gestational choriocarcinoma (GC) is a malignant condition that develops from trophoblastic cells originating from a previous pregnancy, eutopic or ectopic. Metastatic choriocarcinoma is often diagnosed in the absence of a primary uterine or ovarian tumor, presumably because the latter has undergone complete necrosis. GC rapidly metastasizes spreading to lungs, brain, bones, bone marrow, liver, and other organs, but responds well to chemotherapy. Material and methods. We presented the case of a 25-year-old woman with critical evolution after being diagnosed with choriocarcinoma following a complete hydatidiform mole pregnancy. Even though the patient initially received proper treatment, due to poor follow-up compliance, the condition led to invasive metastases. When it spread to the musculoskeletal system and other organs, doctors were able to link symptoms to the choriocarcinoma diagnosis and chemotherapy was initiated. Unfortunately, the patient succumbed due to intracranial hemorrhage. Discussions. GC is a highly and fast invasive malignancy, with rapidly growing tumors. It is often associated with hemorrhage, ischemic necrosis, and secondary inflammation. Often, by the time the tumor is discovered, X-rays of the chest and bones have already shown metastatic lesions. Chemotherapy success depends on the early detection and diagnosis of tumors after pregnancy. Conclusions. Even though the initial diagnosis and treatment should have led to a favorable outcome, the patient’s poor compliance was followed by rapid progression of the disease and, finally, exitus.

Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): Continuation of anti-EGFR therapy while switching chemotherapy regimen.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 744-744 ◽  
Author(s):  
Liubov Yu Vladimirova ◽  
Natalya A Abramova ◽  
Oleg Ivanovich Kit
Keyword(s):  
Tumor Control ◽  
Egfr Inhibition ◽  
Metastatic Lesions ◽  
Line Therapy ◽  
Acneiform Rash ◽  
Dermatologic Toxicity ◽  
Liver And Kidney ◽  
Visceral Metastases ◽  
Kidney Functions ◽  
Unacceptable Toxicity

744 Background: The purpose of the study was to assess the effeciency and safety of continuing of EGFR-inhibition while switching the chemotherapy (CT) from FOLFOX+Cetuximab (C) as the 1st-line to FOLFIRI+С as the 2nd-line treatment for pts with RAS wt mCRC. Methods: Pts with RAS wt mCRC were enrolled to the pilot study according to inclusion criteria: ECOG≤2, normal bone marrow, liver and kidney functions, no brain metastases, measurable metastatic lesions. The therapy included: the 1st-line with FOLFOX-6+C until progression, then FOLFIRI+C as the 2nd-line therapy. The treatment continued until progression or unacceptable toxicity. Response rate (RR), PFS after the 1st and the 2ndlines of treatment as well as toxicity were evaluated. Results: 20 pts (11 men, 9 women), 38-58 years old, mean age 48.3±1.3 years, were recruited. All pts had multiple visceral metastases: to the liver –30.0%(6), lungs and pleura – 20.0%(4), liver and lungs – 50.0%(10), including the bone metastases – 15.0%(3). The RR was 85.0 %(17), including PR - 4(20.0%) and SD - 13(65.5%). Median PFS after the 1st-line therapy was 12.3±2.6 months, median PFS after the 2nd-line therapy - 6.5±2.8 months. Median OS was not reached yet. Adverse events included: neutropenia Gd2 – 30.0%(6), Gd3 – 20.0%(4), anemia Gd2 – 10.0%(2), stomatitis Gd2-3 – 20.0%(4), diarrhea Gd2 - 55.0%(11), thrombophlebitis – 10.0%(2). C-associated dermatologic toxicity: acneiform rash Gd2-3 – 85.0%(17), skin itching Gd2 - 30.0%(6), panaritium Gd1-2 -30.0%(6), blepharitis Gd1-2 – 10.0%(2), hypertrichosis – 20.0%(4). Conclusions: Continuing EGFR-inhibition with C while switching CT regimens beyond progression provided significant tumor control and was not accompanied by unacceptable toxicity. This strategy deserves futher evaluation in randomized studies in EGFR-dependent mCRC pts.

Sign in / Sign up

Export Citation Format

Share Document